Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer

NCT03276013 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Neoplasms

Interventions

DRUG: Pembrolizumab

Sponsor

Vall d'Hebron Institute of Oncology